Close

Momenta Phama (MNTA) Reports Results From Phase 1/2 Trial of Necuparanib

October 9, 2014 4:16 PM EDT Send to a Friend
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced top-line results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login